The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.

Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...

Danish Prime Minister Mette Frederiksen met with business leaders including the head of Novo Nordisk A/S to discuss potential ...

Historical Prices for Novo Nordisk A/S (B Shares) ADRhedged Sustainability Rating Investment Policy Terms funds category comparison Investment Trust Indices Commodities Currencies Stocks ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.